Pan-BET inhibition using (+)-JQ1 has shown anti-proliferative effects against a multitude of haematological and solid malignancies, including breast,29,30 colorectal,31 and brain cancers,32,33 as well as multiple myeloma (MM),34,35 leukaemia,36–38 and lymphoma.35,38,39(+)-JQ1 was key to establishing the mechanistic significance of BET inhibition, however was unsuitable for clinical progression due to its short half-life26 and thus its required dose concentrations being above tolerable levels in vivo.40 The gene discussed is DNER; the disease is plasma cell myeloma.